(SBIO) ALPS Medical Breakthroughs - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US00162Q5936 • Health
SBIO: Cancer, Gene, Therapy, Vaccine, Diagnostic, Treatment
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials. ‣ Company URL: http://www.alpsfunds.com ‣ Domicile: United States
Additional Sources for SBIO ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SBIO ETF Overview
| Market Cap in USD | 103m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2014-12-30 |
SBIO ETF Ratings
| Growth 5y | -18.8% |
| Fundamental | - |
| Dividend | 44.2% |
| Rel. Strength Industry | -91.7 |
| Analysts | - |
| Fair Price Momentum | 28.70 USD |
| Fair Price DCF | - |
SBIO Dividends
| Dividend Yield 12m | 2.22% |
| Yield on Cost 5y | 1.86% |
| Annual Growth 5y | 306.64% |
| Payout Consistency | 33.5% |
SBIO Growth Ratios
| Growth Correlation 3m | -85.3% |
| Growth Correlation 12m | 41% |
| Growth Correlation 5y | -50.8% |
| CAGR 5y | -3.40% |
| CAGR/Mean DD 5y | -0.09 |
| Sharpe Ratio 12m | 0.05 |
| Alpha | -25.04 |
| Beta | 1.00 |
| Volatility | 37.29% |
| Current Volume | 22.8k |
| Average Volume 20d | 12.6k |
What is the price of SBIO stocks?
As of January 23, 2025, the stock is trading at USD 32.05 with a total of 22,792 shares traded.
Over the past week, the price has changed by +3.48%, over one month by -5.19%, over three months by -15.63% and over the past year by +2.24%.
As of January 23, 2025, the stock is trading at USD 32.05 with a total of 22,792 shares traded.
Over the past week, the price has changed by +3.48%, over one month by -5.19%, over three months by -15.63% and over the past year by +2.24%.
Is ALPS Medical Breakthroughs a good stock to buy?
Neither. Based on ValueRay Analyses, ALPS Medical Breakthroughs is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -18.79 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SBIO as of January 2025 is 28.70. This means that SBIO is currently overvalued and has a potential downside of -10.45%.
Neither. Based on ValueRay Analyses, ALPS Medical Breakthroughs is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -18.79 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SBIO as of January 2025 is 28.70. This means that SBIO is currently overvalued and has a potential downside of -10.45%.
Is SBIO a buy, sell or hold?
ALPS Medical Breakthroughs has no consensus analysts rating.
ALPS Medical Breakthroughs has no consensus analysts rating.
What are the forecast for SBIO stock price target?
According to ValueRays Forecast Model, SBIO ALPS Medical Breakthroughs will be worth about 31.9 in January 2026. The stock is currently trading at 32.05. This means that the stock has a potential downside of -0.41%.
According to ValueRays Forecast Model, SBIO ALPS Medical Breakthroughs will be worth about 31.9 in January 2026. The stock is currently trading at 32.05. This means that the stock has a potential downside of -0.41%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 31.9 | -0.4% |